WO1999036422A1 - Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme - Google Patents

Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme Download PDF

Info

Publication number
WO1999036422A1
WO1999036422A1 PCT/US1999/000810 US9900810W WO9936422A1 WO 1999036422 A1 WO1999036422 A1 WO 1999036422A1 US 9900810 W US9900810 W US 9900810W WO 9936422 A1 WO9936422 A1 WO 9936422A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
integer
nad synthetase
synthetase enzyme
compounds
Prior art date
Application number
PCT/US1999/000810
Other languages
English (en)
French (fr)
Inventor
Wayne J. Brouillette
Donald Muccio
Mark J. Jedrzejas
Christie G. Brouillette
Yancho Devedjiev
Walter Cristofoli
Lawrence J. Delucas
Jose Gabriel Garcia
Laurent Schmitt
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Priority to AU20317/99A priority Critical patent/AU2031799A/en
Priority to IL13722999A priority patent/IL137229A0/xx
Priority to DE69918799T priority patent/DE69918799D1/de
Priority to AT99900821T priority patent/ATE271555T1/de
Priority to JP2000540138A priority patent/JP2002509149A/ja
Priority to CA002317439A priority patent/CA2317439A1/en
Priority to EP99900821A priority patent/EP1047692B1/en
Priority to IL14151399A priority patent/IL141513A0/xx
Priority to AT99933622T priority patent/ATE256677T1/de
Priority to JP2000566269A priority patent/JP2002523412A/ja
Priority to CA002341506A priority patent/CA2341506A1/en
Priority to EP99933622A priority patent/EP1109805B1/en
Priority to DE69913712T priority patent/DE69913712T2/de
Priority to PCT/US1999/014839 priority patent/WO2000010996A1/en
Priority to AU49639/99A priority patent/AU4963999A/en
Publication of WO1999036422A1 publication Critical patent/WO1999036422A1/en
Priority to US09/617,258 priority patent/US6500852B1/en
Priority to US10/080,279 priority patent/US6861448B2/en
Priority to US10/281,407 priority patent/US6727237B2/en
Priority to AU2003261481A priority patent/AU2003261481A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
PCT/US1999/000810 1998-01-14 1999-01-14 Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme WO1999036422A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
AU20317/99A AU2031799A (en) 1998-01-14 1999-01-14 Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
IL13722999A IL137229A0 (en) 1998-01-14 1999-01-14 Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
DE69918799T DE69918799D1 (de) 1998-01-14 1999-01-14 Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
AT99900821T ATE271555T1 (de) 1998-01-14 1999-01-14 Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
JP2000540138A JP2002509149A (ja) 1998-01-14 1999-01-14 細菌ｎａｄシンテターゼ酵素の阻害剤の合成およびスクリーニング方法、その化合物、ならびに細菌ｎａｄシンテターゼ酵素の阻害剤を用いる細菌および微生物感染の治療方法
CA002317439A CA2317439A1 (en) 1998-01-14 1999-01-14 Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
EP99900821A EP1047692B1 (en) 1998-01-14 1999-01-14 Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors
JP2000566269A JP2002523412A (ja) 1998-08-25 1999-06-30 細菌ｎａｄシンテターゼ阻害剤
AT99933622T ATE256677T1 (de) 1998-08-25 1999-06-30 Inhibitoren der bakteriellen nad synthetase
IL14151399A IL141513A0 (en) 1998-08-25 1999-06-30 Inhibitors of bacterial nad synthetase
CA002341506A CA2341506A1 (en) 1998-08-25 1999-06-30 Inhibitors of bacterial nad synthetase
EP99933622A EP1109805B1 (en) 1998-08-25 1999-06-30 Inhibitors of bacterial nad synthetase
DE69913712T DE69913712T2 (de) 1998-08-25 1999-06-30 Inhibitoren der bakteriellen nad synthetase
PCT/US1999/014839 WO2000010996A1 (en) 1998-08-25 1999-06-30 Inhibitors of bacterial nad synthetase
AU49639/99A AU4963999A (en) 1998-08-25 1999-06-30 Inhibitors of bacterial nad synthetase
US09/617,258 US6500852B1 (en) 1998-01-14 2000-07-14 Inhibitors of bacterial NAD synthetase
US10/080,279 US6861448B2 (en) 1998-01-14 2002-02-22 NAD synthetase inhibitors and uses thereof
US10/281,407 US6727237B2 (en) 1998-01-14 2002-10-25 Inhibitors of bacterial NAD synthetase
AU2003261481A AU2003261481A1 (en) 1998-08-25 2003-11-06 Inhibitors of bacterial NAD synthetase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7139998P 1998-01-14 1998-01-14
US60/071,399 1998-01-14
US9788098P 1998-08-25 1998-08-25
US60/097,880 1998-08-25

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/014839 Continuation-In-Part WO2000010996A1 (en) 1998-01-14 1999-06-30 Inhibitors of bacterial nad synthetase
US09/617,258 Continuation-In-Part US6500852B1 (en) 1998-01-14 2000-07-14 Inhibitors of bacterial NAD synthetase
US09/617,258 Continuation US6500852B1 (en) 1998-01-14 2000-07-14 Inhibitors of bacterial NAD synthetase

Publications (1)

Publication Number Publication Date
WO1999036422A1 true WO1999036422A1 (en) 1999-07-22

Family

ID=26752172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000810 WO1999036422A1 (en) 1998-01-14 1999-01-14 Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme

Country Status (9)

Country Link
US (2) US6500852B1 (US06727237-20040427-C00087.png)
EP (1) EP1047692B1 (US06727237-20040427-C00087.png)
JP (1) JP2002509149A (US06727237-20040427-C00087.png)
AT (1) ATE271555T1 (US06727237-20040427-C00087.png)
AU (1) AU2031799A (US06727237-20040427-C00087.png)
CA (1) CA2317439A1 (US06727237-20040427-C00087.png)
DE (1) DE69918799D1 (US06727237-20040427-C00087.png)
IL (1) IL137229A0 (US06727237-20040427-C00087.png)
WO (1) WO1999036422A1 (US06727237-20040427-C00087.png)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000197A2 (en) * 1999-06-29 2001-01-04 The Uab Research Foundation Methods of treating fungal infections with inhibitors of nad synthetase enzyme
WO2001055443A1 (en) * 2000-01-31 2001-08-02 Pharmacia & Upjohn Company Crystallization and structure determination of staphylococcus aureus nad synthetase
WO2002007516A2 (en) * 2000-07-14 2002-01-31 The Uab Research Foundation Uses for nad synthetase inhibitors
WO2001023330A3 (en) * 1999-09-29 2002-05-10 Upjohn Co Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6500852B1 (en) 1998-01-14 2002-12-31 University Of Alabama Research Foundation Inhibitors of bacterial NAD synthetase
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
WO2005002337A1 (en) * 2003-04-02 2005-01-13 Virtual Drug Development, Inc. Disinfectant compositions and methods
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
WO2005054198A2 (en) * 2003-12-05 2005-06-16 University Of Bath Therapeutics use of pyridinium compounds to modulate naadp activity
EP1652839A2 (en) * 1999-10-28 2006-05-03 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2007005845A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US7514457B2 (en) 2005-05-31 2009-04-07 Pfizer Inc. Substituted aryloxymethyl bicyclicmethyl acetamide compounds
US7696240B2 (en) 2005-12-15 2010-04-13 Hoffmann-La Roche Inc. Fused pyrrole derivatives
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
US8940901B2 (en) 2010-11-11 2015-01-27 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US8993560B2 (en) 2011-03-11 2015-03-31 Glaxo Group Limited Compounds

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003245575A1 (en) * 2002-06-19 2004-01-06 University Of Rochester Oligonucleotide directed misfolding of rna
ATE554766T1 (de) * 2003-06-27 2012-05-15 Jackson H M Found Military Med Amphiphile pyridinium-verbindungen, herstellungsverfahren und ihre verwendung
JP5629447B2 (ja) * 2009-10-07 2014-11-19 株式会社セイシン企業 粒子性状の測定方法及び装置並びに測定試料の調製装置
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
CN110074138B (zh) * 2019-06-18 2020-05-08 江西顺泉生物科技有限公司 一种解淀粉芽孢杆菌油悬浮剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289777A (en) * 1978-12-28 1981-09-15 Schering, Aktiengesellschaft Quinolonecarboxylic acid derivatives and pharmaceutical preparations thereof for treatment of an allergic disease of the respiratory tract
EP0585722A1 (en) * 1992-08-21 1994-03-09 Eisai Co., Ltd. Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275068A (en) 1977-08-29 1981-06-23 Siegfried Ag Lipid lowering alkylene glycols and ester derivatives thereof
US4544741A (en) 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
JPS59198995A (ja) 1983-04-25 1984-11-10 Toyo Jozo Co Ltd Ｎａｄ合成酵素を用いる測定法
US5206146A (en) 1983-04-25 1993-04-27 Asahi Kasei Kogyo Kabushiki Kaisha Assay method using NAD synthetase
JPS60120987A (ja) 1983-12-05 1985-06-28 Kikkoman Corp 固定化された微生物菌体もしくは酵素の製法
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
EP0196530A3 (de) 1985-03-26 1989-03-22 CTA Finanz AG Mittel und Verfahren zur Beschleunigung des Wachstums, zur Optimierung der Fruchtbarkeit und zur Stimulierung des Immunsystems bei Mensch und Tier
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3752238T2 (de) 1986-09-10 1999-05-06 Asahi Chemical Ind Neue NAD-Synthetase gebrauchende Methode
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JP2694361B2 (ja) 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
ATE114114T1 (de) 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
CZ284437B6 (cs) 1991-04-17 1998-11-11 Hoechst Marion Roussel, Inc. Substituované (pyridinylamino)-benzisoxazoly a -benzo[b]thiofeny, způsob jejich přípravy farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin
ES2143992T3 (es) 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
EP0561626B1 (en) 1992-03-17 1998-08-12 Unitika Ltd. A method for enzymatic analysis and reagent therefor
WO1994022842A1 (en) 1993-03-29 1994-10-13 Basf Aktiengesellschaft 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance
IT1271352B (it) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9320115D0 (en) 1993-09-29 1993-11-17 Glaxo Group Ltd Process
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
WO1996004266A2 (de) 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
TR199700625T1 (xx) 1995-01-10 1998-02-21 Smithkline Beecham S.P.A. Osteoporoz (kemik erimesi) tedavisinde yararl� olan indol t�revleri.
CA2213249A1 (en) 1995-02-17 1996-08-22 Mitsubishi-Tokyo Pharmaceuticals, Inc. Process for producing indoline compounds and intermediates for the production of the same
CN1184425A (zh) 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
US6037123A (en) 1995-09-15 2000-03-14 Microcide Pharmaceuticals, Inc. Methods of screening for compounds active on Staphylococcus aureus target genes
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US5849764A (en) 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
FR2744452B1 (fr) 1996-02-06 1998-03-06 Cird Galderma Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US5998438A (en) 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US5981550A (en) 1997-06-05 1999-11-09 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6046136A (en) 1997-06-24 2000-04-04 Zeneca Limited Herbicidal heterocyclic N-oxides compounds
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
WO1999012951A1 (en) 1997-09-11 1999-03-18 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
CA2341506A1 (en) 1998-08-25 2000-03-02 The Uab Research Foundation Inhibitors of bacterial nad synthetase
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289777A (en) * 1978-12-28 1981-09-15 Schering, Aktiengesellschaft Quinolonecarboxylic acid derivatives and pharmaceutical preparations thereof for treatment of an allergic disease of the respiratory tract
EP0585722A1 (en) * 1992-08-21 1994-03-09 Eisai Co., Ltd. Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500852B1 (en) 1998-01-14 2002-12-31 University Of Alabama Research Foundation Inhibitors of bacterial NAD synthetase
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6727237B2 (en) 1998-01-14 2004-04-27 Wayne J. Brouillette Inhibitors of bacterial NAD synthetase
WO2001000197A2 (en) * 1999-06-29 2001-01-04 The Uab Research Foundation Methods of treating fungal infections with inhibitors of nad synthetase enzyme
WO2001000197A3 (en) * 1999-06-29 2001-09-07 Uab Research Foundation Methods of treating fungal infections with inhibitors of nad synthetase enzyme
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
WO2001023330A3 (en) * 1999-09-29 2002-05-10 Upjohn Co Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
US7377894B2 (en) 1999-09-29 2008-05-27 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
EP1652839A3 (en) * 1999-10-28 2006-07-05 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
EP1652839A2 (en) * 1999-10-28 2006-05-03 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2001055443A1 (en) * 2000-01-31 2001-08-02 Pharmacia & Upjohn Company Crystallization and structure determination of staphylococcus aureus nad synthetase
US6988041B2 (en) 2000-01-31 2006-01-17 Pharmacia & Upjohn Company Crystallization and structure determination of Staphylococcus aureus NAD synthetase
WO2002007516A3 (en) * 2000-07-14 2002-06-27 Uab Research Foundation Uses for nad synthetase inhibitors
WO2002007516A2 (en) * 2000-07-14 2002-01-31 The Uab Research Foundation Uses for nad synthetase inhibitors
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2005002337A1 (en) * 2003-04-02 2005-01-13 Virtual Drug Development, Inc. Disinfectant compositions and methods
WO2005054198A3 (en) * 2003-12-05 2005-09-15 Univ Bath Therapeutics use of pyridinium compounds to modulate naadp activity
WO2005054198A2 (en) * 2003-12-05 2005-06-16 University Of Bath Therapeutics use of pyridinium compounds to modulate naadp activity
US8710232B2 (en) 2004-04-22 2014-04-29 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives used as TAFIa inhibitors
US7514457B2 (en) 2005-05-31 2009-04-07 Pfizer Inc. Substituted aryloxymethyl bicyclicmethyl acetamide compounds
WO2007005845A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US7956220B2 (en) 2005-07-01 2011-06-07 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US7696240B2 (en) 2005-12-15 2010-04-13 Hoffmann-La Roche Inc. Fused pyrrole derivatives
US8940901B2 (en) 2010-11-11 2015-01-27 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US8993560B2 (en) 2011-03-11 2015-03-31 Glaxo Group Limited Compounds
US9447074B2 (en) 2011-03-11 2016-09-20 Glaxo Group Limited Compounds

Also Published As

Publication number Publication date
US20040063758A1 (en) 2004-04-01
US6727237B2 (en) 2004-04-27
EP1047692B1 (en) 2004-07-21
CA2317439A1 (en) 1999-07-22
JP2002509149A (ja) 2002-03-26
US6500852B1 (en) 2002-12-31
DE69918799D1 (de) 2004-08-26
IL137229A0 (en) 2001-07-24
AU2031799A (en) 1999-08-02
EP1047692A1 (en) 2000-11-02
ATE271555T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
EP1047692B1 (en) Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof and methods of treating bacterial and microbial infections with these inhibitors
EP1109805A1 (en) Inhibitors of bacterial nad synthetase
Pirrung et al. High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure− Activity Relationships in Novel Inhibitors of Escherichia c oli LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties
Zhao et al. Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates
Lin et al. Practical synthesis of hydroxamate-derived siderophore components by an indirect oxidation method and syntheses of a DIG− siderophore conjugate and a biotin− siderophore conjugate
Qureshi et al. Design, synthesis, in-silico studies and biological screening of quinazolinone analogues as potential antibacterial agents against MRSA
CZ200443A3 (cs) Heterocyklické sloučeniny a jejich použití jakožto inhibitorů D@Ala@D@ala ligasy
CN114230519A (zh) 一类具有抗耐药菌活性的截短侧耳素肉桂酸酯类化合物及其合成方法和应用
Yi et al. Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent pleuromutilin derivatives with a substituted piperazine moiety
KR101246179B1 (ko) 펩티드 화합물
Yi et al. Novel pyridinium cationic pleuromutilin analogues overcoming bacterial multidrug resistance
Granata et al. Synthesis of a calix [4] arene derivative exposing multiple units of fucose and preliminary investigation as a potential broad-spectrum antibiofilm agent
Kim et al. N (2)-Substituted D, L-Cycloserine Derivatives Synthesis and Evaluation as Alanine Racemase Inhibitors
Sethuvasan et al. Synthesis, spectral characterization, crystal structure and molecular docking study of 2, 7-diaryl-1, 4-diazepan-5-ones
AU2003261481A1 (en) Inhibitors of bacterial NAD synthetase
Gao et al. Design, synthesis, and biological evaluation of vanillin hydroxamic acid derivatives as novel peptide deformylase inhibitors
Sachdevaa et al. Synthesis, evaluation and in silico studies of 1, 8-naphthyridine derivatives against antimicrobial activity
Rahmania et al. In silico and in vitro assay of Hexagamavunon-6 analogs, Dibenzilyden-N-Methyl-4-piperidone as antibacterial agents
CN113372296A (zh) 用于抑制多重耐药的金黄色葡萄球菌的硒啉类化合物及用途
US20050251345A1 (en) Small molecules and a pharmacophore model for inhibition of anthrax lethal factor
JP2005504123A (ja) 細菌性感染を治療又は予防するための方法及び組成物
e Sana et al. Syntheses and antimicrobial activities of amide derivatives of 4-[(2-isopropyl-5-methylcyclohexyl) oxo]-4-oxobutanoic acid
Rababa et al. Synthesis, biological activity and DFT studies of 1, 3, 4-oxadiazole ring in combination with pyridinium salt
EP3535242B1 (en) Dna primase and gyrase inhibitors
Sargsyan et al. The Synthesis and in vitro Study of 9-fluorenylmethoxycarbonyl Protected Non-Protein Amino Acids Antimicrobial Activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 20317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 137229

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2317439

Country of ref document: CA

Ref country code: CA

Ref document number: 2317439

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 540138

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999900821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999900821

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999900821

Country of ref document: EP